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Abstract (250 words) 
Monoallelic mutations of DNAJB11 were recently described in seven pedigrees with atypical clinical 
presentations of autosomal dominant polycystic kidney disease (ADPKD). DNAJB11 encodes one of 
the main cofactors of the endoplasmic reticulum chaperon BiP, a heat-shock protein required for 
efficient protein folding and trafficking. Here we conducted an international collaborative study to 
better characterize the DNAJB11-associated phenotype. Thirteen different loss-of-function variants 
were identified in twenty new pedigrees (54 affected individuals) by targeted next-generation 
sequencing, whole-exome sequencing or whole-genome sequencing. Amongst the 77 patients (27 
pedigrees) now in total reported, 32 reached ESRD (range, 55-89y), with a median age of 75 years 
(0.95 CI, 72.5-77.5 years), and without a significant difference between males and females. While a 
majority of patients presented with non-enlarged polycystic kidneys, renal cysts were 
inconsistently identified in patients <45y. Vascular phenotypes, including intracranial aneurysms, 
dilatation of the thoracic aorta and dissection of a carotid artery were present in four 
pedigrees. We accessed Genomics England 100,000 genomes project data, and identified 
pathogenic variants of DNAJB11 in 9/3934 probands with various renal and urinary tracts 
disorders. The clinical diagnosis was cystic kidney disease for eight probands and 
nephrocalcinosis for one proband; no additional pathogenic variants likely explaining the renal 
disease were identified. Using the publicly available GnomAD database, DNAJB11 genetic 
prevalence was calculated at 0.85/10.000 individuals (0.95 CI, 0.34-2.02). Establishing a precise 
diagnosis in atypical cystic or interstitial nephropathies is crucial, with important implications 
in terms of follow-up, genetic counseling, prognostic evaluation, therapeutic management, and for 
the selection of living kidney donors. 
Introduction 
The two major genes causing autosomal dominant polycystic kidney disease (ADPKD) are PKD1 
(MIM: 601313), encoding polycystin 1 (PC1), and PKD2 (MIM: 173910) encoding polycystin 2 (PC2), 
identified in 72%–78% and 15%–18% of families, respectively.1 Three additional genes have been 
recently identified in pedigrees with an atypical ADPKD presentation: GANAB (OMIM: 104160), 
DNAJB11 (OMIM: 618061) and ALG9 (OMIM: 606941); all three genes encoding proteins involved in 
the maturation and processing of membrane and secreted proteins.1-6 Other genes might 
occasionally phenocopy ADPKD clinical presentation, including notably HNF1B, with dominantly 
inherited mutations associated with a highly heterogeneous phenotypic spectrum, including maturity 
onset diabetes of the young, a personal or familial history of urogenital malformations, early onset 
gout, the presence of elevated liver enzymes or hypomagnesaemia and/or bilateral renal cysts.7 
Monoallelic mutations of PRKCSH, SEC63, ALG8, SEC61B and LRP5 are associated with autosomal 
dominant polycystic liver disease (ADPLD), characterized by the development of hepatic cysts, with 
occasional renal cysts.1,3,8 While the expansion of the ADPKD genetic landscape allows a better 
understanding of its clinical variability, the phenotypic and prognostic characterization of these 
newly identified disorders is still limited to a small number of pedigrees.  
Monoallelic pathogenic variants to DNAJB11 have recently been reported in 23 patients from seven 
ADPKD-like pedigrees, who presented with non-enlarged or atrophic cystic kidneys, and late-onset 
end-stage renal disease (ESRD).4 DNAJB11, located on chromosome 3q27.3, encodes a soluble 
glycoprotein of the endoplasmic reticulum (ER), DNAJB11, which acts as one of the main cofactor of 
the chaperone BiP (for binding immunological protein, alias GRP78).9 BiP regulates protein folding 
and assembly, targets misfolded proteins to ER degradation, and acts as a master regulator of the 
unfolded protein response (UPR), an adaptive cellular response to ER stress.10 DNAJB11 loss is 
associated with impaired polycystin 1 (PC1) maturation.4 However, kidney function decline in 
DNAJB11 individuals seems also the result of the development of extensive interstitial fibrosis, 
reminiscent of autosomal dominant tubulo-interstitial kidney disease (ADTKD).4,11 Interestingly, 
defective proteostasis caused by DNAJB11 variants might also affect the trafficking of uromodulin, 
mimicking the ADTKD-UMOD phenotype.4 
This study presents the clinical, radiological and genetic characterization of 54 DNAJB11-affected 
individuals from 20 pedigrees identified in France, the United Kingdom, the Netherlands, United 
States and Australia. We also describe the renal survival in a cohort of 77 individuals, combining the 
20 newly identified (54 individuals) and the seven reported pedigrees (23 individuals). Last, we 
explore the prevalence of DNAJB11 variants in a large cohort of patients affected by various possibly 
inherited kidney diseases, and in the publicly available population-sequencing database GnomAD. 
  
RESULTS 
Patient characteristics and description of the mutation spectrum 
Twenty DNAJB11 pedigrees were identified in the six referral-centers performing molecular 
diagnostics of cystic kidney diseases involved in the study (Supplemental Figure 1). In the 20 
probands, the median age at referral for genetic diagnosis was 63.5 years (range 45-80), and the 
presumptive clinical diagnosis, or primary reasons for referral for genetic testing was ADPKD in 17 
pedigrees, ADTKD in two pedigrees and nephropathy of unknown etiology in one pedigree. Familial 
studies led to the identification of 54 affected individuals in total (35 female patients). The thirteen 
different pathogenic variants identified in the 20 newly reported pedigrees were all predicted loss-of-
function variants, including four short frameshifting deletions or insertions (six pedigrees), seven 
nonsense variants (11 pedigrees), one start-codon mutation (two pedigrees) and one substitution of 
the last nucleotide of exon 6, predicted to weaken the splicing donor site (one pedigree) (Table 1 and 
Figure 1).  
Diagnosis and clinical features in DNAJB11 patients 
Kidney function and renal survival 
To provide a better description of the DNAJB11-associated renal outcome, we combined the 23 
previously identified and the 54 newly reported DNAJB11-affected individuals. The distribution of 
patients according to Chronic Kidney Disease (CKD) stage at last follow-up is reported in Table 2.No 
significant proteinuria was reported in any of the patients identified. Before or at age 55, a high 
majority of the patients were classified at CKD stages 1 or 2 (94%, n=17/18), while after age 55, 73% 
of the patients were classified at CKD stages 4 or 5 (n=44/59). Renal function at a given age did not 
differ between males and females (P=0.428, Figure 2A). In total, 32 individuals reached ESRD, at ages 
ranging from 55 to 89y. Median age at ESRD obtained by Kaplan-Meier curve analysis was 75 years 
(0.95 CI, 72.5-77.5 years), and renal survival did not differ according to sex (Figure 2B). At ages 60, 70, 
and 80 years, probabilities of having reached ESRD were 4.4% (standard error [SE] =3%), 37.4% 
(SE=7.6), and 82.2% (SE=7.6). Renal histology was available for three patients, Individual II.1 from 
Family A, II.1 from Family C, and III.1 from Family R, showing for the two first cases diffuse interstitial 
fibrosis and tubular dilatations (Supplemental Figure 2), while the third patient had minimal 
interstitial fibrosis and tubular dilatations at an early stage of the disease (CKD stage 1, 43 years). No 
specific glomerular lesions in the non-sclerotic glomeruli were present in any of these three cases. 
 Radiological presentation  
Details regarding morphology of the kidneys in the 54 DNAJB11 individuals, when available, are 
reported in Table 1, illustrative imaging are displayed on Figure 3 and Supplemental figure 3. Multiple 
bilateral small cysts were reported in a vast majority of the patients, and mean kidney length 
(calculated as the mean of the average length of both kidneys) was 11.6 cm [range 7.6-19.25 cm, 
n=36]. Mayo Imaging Classification was applied in 39 individuals: 8 (20.5%) were classified as 1A, 2 
(5.1%) 1B, 1 (2.6%) 2A, and 28 (71.8%) were classified as 2B. In younger patients, renal cysts were 
inconsistently identified. Indeed, in pedigree A, no cysts were identified by renal ultrasound 
examination in individual IV.4 at age 34, and the patient was initially considered unaffected. 
Following the identification of the familial mutation, an MRI was performed and confirmed the 
presence of small millimeter-sized renal and liver cysts. In pedigree R, the 43 years-old female 
individual III.1, who was a candidate as a living kidney donor for her mother II.1, was initially 
considered unaffected based on imaging. The subsequent identification of the familial DNAJB11 
mutation in her prompted her physicians to review the contrast-enhanced CT imaging, which showed 
a small number of millimeter-sized kidney cysts, and one liver cyst. In some affected individuals, no 
or few renal cysts were identified at an advanced stage of the nephropathy. In participant II.2 of the 
pedigree G, who had reached CKD stage 5 at age 74, only a small number of renal cysts were 
identified by MRI (Figure 3F). In the subject II.3 from pedigree L, who had an eGFR of 
30ml/min/1.73m² at age 62, a non-contrast enhanced CT scan examination did not show any renal or 
liver cysts. Only one patient in this cohort, individual II.2 from pedigree I, had enlarged kidneys when 
he reached ESRD, with left and right kidney lengths of 19 and 19.5 cm, and a total kidney volume 
(TKV) of 1445 ml (Figure 3H). No other likely pathogenic variants were identified in PKD1, PKD2, or 
any other cystogenes. 
Extra-renal phenotypes 
Information regarding the presence of liver cysts was available in 39 subjects, and at least one liver 
cyst was reported in 19 patients (48.7%) (e.g. Figure 3N and 3O), but most of the patients did not 
have clinically significant polycystic liver disease. In female individual II.1 from pedigree A, abdominal 
pain and jaundice led to the aspiration of a 10cm liver cyst compressing the common bile duct 
(Supplemental Figure 3A). Female subject II.2 from family K had multiple large liver cysts at age 74 
(Supplemental Figure 3F). Gout was only reported in individual II.3 from pedigree I, a 79 year-old 
male approaching ESRD, and in a 64-year-old male participant of the 100,000-genome project, at CKD 
stage 3. 
Vascular phenotypes were reported in four pedigrees. Subject I.1 from Family F underwent a cerebral 
MRI at the age of 57 years because of chronic headache. This led to the detection of a saccular 
aneurysm of the anterior circulation, measuring 6 mm of diameter. As most of her family members 
lived in different countries, to date, no affected relative has been identified and screened for ICA. In 
subject II.4 from Family L, systematic screening at age 66 led to the incidental diagnosis of a 3mm-
sized ICA of the posterior circulation, for which simple imaging monitoring was recommended. No 
other case was identified in the family, his mother died of ischemic cerebral vascular accident at age 
68. In family O, a spontaneous dissection of the left carotid was reported in individual I.1. Last, in
family P, aneurysms of the ascending thoracic aorta were diagnosed at age 45 and 50 in two siblings. 
The proband had surgical replacement of the ascending aorta at the age of 46 years.  
DNAJB11 prevalence in patients with genetically unresolved nephropathies 
The Genomics England 100,000 Genomes Project data was analyzed for rare and likely pathogenic 
variants in DNAJB11. As of September 2019, whole genome sequencing (WGS) was performed in 
35042 probands affected by rare diseases, including 3934 probands with various renal and urinary 
tracts disorders (see details in Table S1). Pathogenic variants (truncating or otherwise described) of 
DNAJB11 were searched for in the participants with renal disorders, and identified in eight probands 
(nine individuals) in the cystic kidney disease subgroup, and one proband in the wider renal and 
urinary tract disease cohort. Details on the variants identified and the clinical information available 
for these nine probands are listed in Table 3. No other pathogenic variants likely to explain the renal 
disorder were identified in any of the ten individuals, and variants of unknown significance in other 
cystogenes are reported in the footnotes of Table 3. While incomplete phenotypic data was available 
for these patients, multiple bilateral renal cysts were reported in eight individuals out of nine, and 
liver cysts were reported in two individuals. Two unrelated individuals had abdominal wall hernias.  
DNAJB11-nephropathy genetic prevalence  
Eleven DNAJB11 likely pathogenic variants were identified in twelve subjects from the GnomAD 
database (Table S2). Thus, DNAJB11 genetic prevalence is estimated at 0.85 (95% CI, 0.44-
1.48)/10,000 in the whole GnomAD population (n=141456). As the GnomAD database comprises 
patients with different ethnicities, we also considered separately the European population 
(n=64603), in which 6 individuals were found to have a DNAJB11 pathogenic variant, corresponding 
to a prevalence of 0.93 (95% CI, 0.34-2.02)/10,000. 
 
Discussion 
The tremendous progress in genomics in the past 10 years has translated into an acceleration 
in gene discoveries. The newly identified inherited disorders are generally rare diseases, described in 
a handful of pedigrees; solved “diagnosis odysseys”. The possibility to offer early screening to at-risk 
relatives is a major advantage of obtaining a genetic diagnosis, however, the paucity of 
clinical/phenotypic data for solved rare diseases can be a limitation to provide adequate clinical and 
prognosis information. In this study, the collaboration of six expert inherited kidney disease centers 
across three continents has provided a description of the phenotype in a much larger DNAJB11-
nephropathy population, only two years after the first identification of the gene. 
In the 27 DNAJB11 families clinically characterized to date, renal insufficiency and/or cystic 
disease were present in all the mutations carriers, including relatives identified through family 
studies, suggesting that monoallelic DNAJB11 pathogenic variants are highly penetrant. No additional 
variants, in PKD1, PKD2, or other cystogenes, were identified in any of the family probands, despite 
careful analysis by WES, WGS or by targeted next generation sequencing (NGS). In the additional 10 
individuals (9 pedigrees) identified through the Genomes England 100,000 Genomes Project, no 
other pathogenic variant likely to explain the renal disorders (renal cystic disease in 9 individuals, and 
unexplained CKD stage 3 with nephrocalcinosis in one individual) were identified; further supporting 
high penetrance of DNAJB11 variants.  Hence, the genetic prevalence of DNAJB11 loss-of-function 
variants in the GnomAD population-sequencing database, of 0.85 in 10000 individuals, appears as a 
good lower estimate of the lifetime-risk of developing DNAJB11-nephropathy. Some rare missense 
variants of DNAJB11 identified in GnomAD, not included in our analysis, may actually be pathogenic, 
resulting in a possible underestimation of this genetic prevalence. However, a large majority (~88%) 
of the mutations identified in affected individuals are loss-of-function variants, and thus we have 
presently limited knowledge of DNAJB11 missense variants functional consequences. A similar 
approach was previously employed that resulted in an estimated ADPKD genetic prevalence (PKD1 
and PKD2) of 9.3 in 10.000 individuals.12  While these figures suggest that DNAJB11 disease is only 
~11 times less common than PKD1/PKD2 associated ADPKD, the contribution of DNAJB11 in ADPKD 
patients cohort appears significantly lower. Indeed, as of September 2019, DNAJB11 pathogenic 
variants were identified in 2.6% of the 228 PKD1/PKD2 negative pedigrees of the Genkyst cohort (6 
pedigrees including one previously reported family), and 1.3% of the 457 PKD1/PKD2 negative 
pedigrees analyzed at Mayo Clinic (6 pedigrees including three previously reported families).4 
However, the median age at diagnosis of 63.5 years in the probands suggest that a majority of 
DNAJB11 patients remain currently under the radar, due to lack of a clinical phenotype in younger 
individuals. In addition, one has to keep in mind the important variability in terms of clinical 
presentation; with occasionally, no or few renal cysts detected despite advanced kidney disease. For 
this reason, we suggest using the term DNAJB11-nephropathy rather than ADPKD.  
Several younger individuals of this cohort were initially considered unaffected when imaging-
based diagnosis was employed. One of these individuals was even considered as a living-related 
kidney donor.  One of the key message of this study is that imaging-based diagnosis criteria 
developed in PKD1 and PKD2 patient cohorts should not be employed in cases of atypical polycystic 
kidney disease, where only genetic diagnosis can be used to rule out the diagnosis in at-risk 
individuals.13,14 Similarly, prognostic tools based on TKV, such as the Mayo Imaging Classification, or 
the height-adjusted TKV, should not be employed in DNAJB11 patients, as, unlike in PKD1 or PKD2-
associated ADPKD, kidney function decline is not driven mainly by cystogenesis, and hence, kidney 
enlargement does not precede eGFR decline.15-17 
Both ADTKD-UMOD and ADTKD-MUC1 are marked by strong variability in terms of 
progression to ESRD, with ages at ESRD onset ranging from less than 20 years to more than 80 years, 
and respective median ages at ESRD of 56 and 51 years.18-20 In contrast, the DNAJB11 disease course 
appears more consistent amongst individuals and families, with ESRD onset ranging from 55 to 89 
years and median age at ESRD of 75 years.  Moreover, the low prevalence of gout in DNAJB11 
patients (4 in 77 individuals identified to date, ~5.2%) contrasts with the respective estimates of 25-
70% and 7-24% in ADTKD-UMOD and -MUC1 affected individuals, respectively.18-21 The pathogenesis 
of DNAJB11- nephropathy remains incompletely understood. While mature PC1 deficiency likely 
account for the cystic component of the phenotype, kidney function decline seems mainly driven by 
the development of extensive interstitial fibrosis, apparently independent from evident cystic 
expansion. DNAJB11 plays a central role in the maintenance of ER protein homeostasis (or 
proteostasis). Proteostasis requires precise control of protein synthesis, folding, conformational 
maintenance, and degradation. Aging is associated with a declining cellular capacity to maintain 
proteostasis.22,23 Indeed, the proteostasis network is increasingly burdened by misfolded proteins, 
and proteins impaired by oxidative stress. The role of age-related defective proteostasis is regarded 
as a major driver of neurodegenerative disorders, with heavy loads of misfolded proteins gradually 
accumulating in neurons.24 Tubular epithelial cells are likely to be prone to similar sensitivity to aging. 
This could explain the accelerated decline of kidney function after the fifth to sixth decade observed 
consistently in DNAJB11 patients. Comorbidities increasing the misfolded protein load, such as 
obesity, dyslipidemia, diabetes, and chronic inflammation,25 could also play an aggravating role on 
DNAJB11-nephropathy’s course. Larger patients’ cohort, and functional /tissue analyses will be 
needed to better understand DNAJB11 pathogenesis. While no specific treatment is currently 
available to slow the kidney function decline in DNAJB11-associated disease, emerging therapies in 
ADTKD, improving cellular proteostasis, might be of interest in the future. Indeed, a recent study 
demonstrated that toxic accumulation of MUC1 mutant proteins could be rescued by a small 
molecule, rerouting the mutant protein for lysosomal degradation, a therapeutic strategy that might 
be applicable to other proteostasis related disorders.26 
Of interest, different vascular phenotypes were reported in this cohort, notably ICA in two 
pedigrees, carotid dissection in one individual and dilatation of the thoracic aorta in two siblings. 
Interestingly, data generated by the International Mouse Phenotyping Consortium (IPMC) indicates 
that mice with heterozygous inactivation of Dnajb11 exhibit aortic dilatation.27 Abdominal wall 
hernias (AWH) segregated with the disease in two siblings and were reported in two out nine 
pedigrees identified in the Genomes England 100,000 dataset. AWH have been noted more 
frequently in patients with ADPKD as compared to ESRD patients without ADPKD.28 It has been 
hypothesized that AWH result from the combination of altered matrix integrity and increased 
abdominal pressure from cyst burden.29,30 While the latter seems unlikely in DNAJB11 patients, who 
generally present with non-enlarged polycystic kidneys and mild liver involvement, reduced mature 
PC1 might cause altered extracellular matrix organization. Interestingly, AWH and arterial 
phenotypes are also described in hereditary connective tissue disorders such as vascular Ehlers-
Danlos syndrome (vEDS), an autosomal dominant disorder due to mutations of COL3A1 gene.31 A 
recent transcriptome analysis of skin fibroblasts of vEDS patients has highlighted, amongst different 
pathways, significant changes in the expression levels of genes involved in ER-related homeostasis, 
including DNAJB11.32 
In conclusion, our study shows that DNAJB11-disease is a rare but probably underestimated 
cause of CKD, combining clinical features of ADPKD and ADTKD. The association of normal-
sized/atrophic kidneys with millimeter-sized renal and liver cysts should prompt the physicians to 
consider this diagnosis, with important implications in term of follow-up, prognostic evaluation, 
therapeutic management and for the selection of living kidney donors. DNAJB11-nephropathy and 
classical ADPKD (i.e. caused by mutations of PKD1 or PKD2) have distinct disease courses, different 
pathogeneses, and will likely necessitate different therapeutic strategies. Although DNAJB11-
nephropathy can present, in some patients, as a phenocopy of ADPKD, it should not be considered, 
to our opinion, as a subtype of ADPKD, but as a distinct disorder.  In the future, increased awareness 
amongst nephrologists, combined with better access to genetic testing, will likely translate in a better 
recognition of the disease, earlier diagnoses in at-risk individuals and, hopefully, into the 
development of specific therapeutic strategies. 
 
 
PATIENTS AND METHODS 
Study participants and clinical analyses 
We collected newly identified DNAJB11 pedigrees in six genetic laboratories of expertise in inherited 
kidney diseases. The identified pedigrees originate from France (Families A to J), the US (Families K to 
M), United Kingdom (Families N to P), Netherlands (Family Q) and Australia (Families R, S and T). 
Families came from various study cohorts: GeneQuest (NCT02112136) (Families A, B, G, I, J), Brest 
University Hospital, France (C, D, E, F, H), the Mayo PKD Center (Families K to M), The National 
Registry of Rare Kidney Diseases (RaDaR) cohort (Family P), the Sheffield Kidney Institute (Families N 
and O), and the KidGen collaborative cohort (Families R to T). The relevant Institutional Review 
Boards or ethics committees approved all studies, and participants gave informed consent. Clinical, 
imaging data and familial information were obtained by review of clinical and study records, and/or 
during medical interviews. Affected relatives’ kidney function was calculated from clinical serum 
creatinine measurements with the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) 
formula. Blood or saliva samples for standard DNA isolation were collected from the probands and all 
available family members.  
Molecular analyses 
Different NGS strategies were employed in the different centers: targeted NGS (TNGS) panels of 9, 15 
and 137 cystogenes in Brest, Sheffield and in Mayo Clinic, respectively, cystogene panel filtered from  
whole exome sequencing in Utrecht, Netherlands, whole genome sequencing for the pedigree from 
Newcastle as part of the 100,000-genome project and in Australia.  The TNGS panel employed in 
Brest (Nimblegen) includes the following genes: PKD1, PKD2, GANAB, DNAJB11, HNF1ϐ, PKHD1, 
UMOD, SEC63, PRKCSH; the TNGS panel employed in Sheffield (SureSelect) includes, in addition to 
the aforementioned genes, the following genes: REN, SEC61A1, TSC1, TSC2, LRP5, AGT. Details about 
the TNGS panel employed in Mayo have been published recently.33  All changes were confirmed by 
Sanger sequencing. When family samples were available, segregation analysis of the variant of 
interest was performed. 
Imaging classification 
Available abdominal CT, MRI and ultrasound images, or/and reports were retrieved from medical 
records. In patients with bilateral renal cysts, Mayo imaging classification was applied.17 Patients 
were classified as typical (Class 1) or atypical (Class 2). Class 1 ADPKD patients were further stratified 
into five subclasses based on height-adjusted TKV and age, whenever available, as previously 
described.17 Individuals with asymmetrical, unilateral, segmental, or lopsided imaging presentations 
were classified as 2A. Individuals with impaired renal function (serum creatinine≥1.5 mg/dl) without 
significant enlargement of the kidneys, defined by an average length <14.5 cm, were classified as 
2B.17  
Statistical analysis 
All statistical analyses were performed using SPSS software, version 20 (IBM Corp), and GraphPad 
Prism, 5.00 for Windows (GraphPad Software, La Jolla California US). Renal survival (time from birth 
to ESRD) was analyzed using the Kaplan-Meier method. Differences between survival curves in male 
and female patients were assessed using a log rank test with a 0.05 significance level. 
Genetic prevalence estimate 
The Genome Aggregation Database (GnomAD, Cambridge, MA) is a collection of 125,748 exome and 
15,708 genome data of unrelated individuals from different origins.34 GnomAD v2.1 data were 
downloaded from http://gnomad.broadinstitute.org. Truncating variants (nonsense, splice, and 
frameshift mutations) and missense variants known to be fully penetrant were inventoried, with 
their respective allele counts, and entered in the calculation of the genetic prevalence. The 95% 
confidence intervals (CIs) for prevalence rates were computed assuming that the observed number 
of cases follows a binomial distribution. 
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Table 1. Pathogenic variants, clinical and radiological features in the 54 affected individuals from 20 DNAJB11 pedigrees 















and if deceased 
cause of death 
Type Age 
Description 










M ESRD (80) NA NA NA NA NA NA NA NA COD uremia at age 80 
II.1 a 







III.2 M ESRD (67) CT 66 MBSC 
R:12.7, L:12.9 
(1169) 
3A Yes Yes 2B Pancreatic cysts 
III.4b 
F 58 (64) CT 66 MBSC 
R:9.5, L:9.3  
(443)




M 92 (41) US 38 
4 small cysts 
LK, 2 small 
cysts RK 
R:13, L:13 
NA No No  NA None 
IV.4 
F 91 (39) MRI 36 
2 small cysts 










F ESRD (61) CT 63 MBSC 
R:14.3, L:14 
(1322) 






M 18 (69) MRI 66 MBSC 
R: 6.2, L: 9 
(206)






and hepatitis (63) 
II.2b 
F 37 (66) MRI 64 MBSC  
R:9.8, L:9.8 
(325)











F ESRD (85) CT 85 MBSC 
R: 8.5, L:10.9 
(713)
3D Yes Yes 2B None 
III.6b 
F 30 (61) US 61 MBSC R:9.4, L:7.6 NA Yes (58) No 2B None 
III.7 
F 32 (63) US 63 
MBSC, micro 
calcifications 






F ESRD (64) CT 66 MBSC 
R:12, L:10 
(381)
S3E Yes  Yes 2B Obesity 
III.6 b
F 24 (78) MRI 74 
MBSC, micro 
calcifications 
R: 9, L:10 NA Yes Yes 2B 
Acute rheumatic 
fever in childhood, 











3E Yes (58) No 2B 













R 9.5, L 10.2 
(223)
3F Yes (74) No 2B None 
II.4 









M ESRD (70) NA NA 
Polycystic 
kidneys 
Normal-sized NA NA NA NA COD prostate cancer 
II.3 b 
F 44 (60) US 61 
MBSC (largest 
34mm) 





F ESRD (80) NA NA 
Polycystic 
kidneys 
NA NA NA NA NA COD uremia (80) 
I.2a 
M ESRD (80) NA NA 
Polycystic 
kidneys 




M ESRD (80) CT 79 
MBSC (largest 
20mm) 
R 14, L 14.5 
(954)
3G Yes  No 1B None 
II.3 
M ESRD (80) MRI 80 MSBC 
R 19, L 19.5 
(1449) 





M 12 (52) US 51 MBSC  
Atrophic 
kidneys 





F 99 (45) MRI 45 
8 small cysts 
LK, 12 RK, 
largest 1.4cm 
R: 13, L:12 
(458)













NA Yes No 2B T2DM (68) 
II.2b 
F ESRD (71) MRI 74  
MBSC, 1 very 















COD CVA (72) 
III.2 
F 68 (61) US 61 
MBSC, largest 
27mm 












I.2 a F ESRD (69) NA NA NA NA NA NA NA NA COD ESRD and CVA 
II.1 a F ESRD (68) NA NA MBSC NA NA NA NA NA COD CVA (68) 













NA NA No NAc None 
II.4b M 25 (67) CT 65 MBSC 
R:10.9, L:9.9 
(542)
3L Yes (64) No 2B 
ICA (posterior, 3mm), 






I.1 F 24 (66) NA NA MBSC NA NA Yes NA NA None 
II.1b M 90 (53) CTw 43 9 small cysts 
R:12.8, L:11.9 
(489)





II.1a M ESRD (76) NA NA NA NA NA NA NA NA None 
II.3b M 29 (72) CT 67 
MBSC, a few 
larger cysts 











II.1 F 100 (44) ceCT 44 
8 cysts RK, 6 
cysts LK 
R: 11, L: 11 S3I No No 1A 
Left unguinal hernia 
repair (25) 
II.2 F 102 (40) ceCT 40 
2 cysts RK, 8 
cysts LK 
R:12.5, L: 12.3 S3J No  No 1A 






II.1a M ESRD (68) US 68 MBSC Non-enlarged NA NA NA 2B None  
III.1b F 74 (50) MRI 50 MBSC 














p.T178fs II.5 F 55(56)e US 56 
MBSC (largest 
11mm) 





I.1 a F ESRD (75)  NA NA NA NA NA Yes NA NA COD uremia (75) 
II.1b F ESRD (69) US 69 MBSC R:13.0, L:10.6 NA Yes No 2B Melanoma 









I.1a M ESRD (75) NA NA NA NA NA NA NA NA COD uremia (75) 





I.1 M ESRD (73) US 75 MBSC R:13.6,L:13.1 NA NA Yes (1) 2B 
COD: Metastatic 
prostate cancer 
II.1b M 67 (55) US 54 
At least seven 
small cortical 
cyst LK and RK 
R:12.5,L:11.6 NA Yes (39) No NA None 
a No blood sample available, the presence of the familial variant was not confirmed.  bProband. cDespite being affected, non-enhanced CT scan did not reveal any renal cyst, the Mayo 
Imaging Classification could not be applied. dLast nucleotide of exon 6, the substitution is predicted to weaken the donor site (BDGP, 0.06 to <0.01; HSF 83.39 to 72.52, and the motif 
entropy score for the donor site goes from +4.51 to -4.94). e24-hours-creatinine clearance is reported instead of CKD-EPI eGFR because the patient is wheelchair bound since childhood 
and has severe sarcopenia 
BMI body-mass index, CVA cerebral vascular accident, COD cause of death, CT computed tomography, ceCT contrast-enhanced CT, ESRD end-stage renal disease, MBSC 
multiple bilateral small cysts, MRI magnetic resonance imaging, NA non available, PD peritoneal dialysis, SLE systemic lupus erythematosus,T2DM Type 2 diabetes mellitus, UTI 
urinary tract infections 
Table 2. Distribution of the 77 DNAJB11-affected individuals according to Chronic Kidney Disease (CKD) 
stage 
CKD stage Number of subjects (%) 
1 14 (18.2%) 
2 9 (11.7%) 
3a 5 (6.5%) 
3b 4 (5.2%) 
4 12 (15.6%) 
5 33 (42.9%) 










M 76 Cystic Kidney disease 
Multiple renal cysts (cortical and medullary), HBP, 




F 81 Cystic Kidney disease 
Multiple renal cysts, HBP, CKDa, Stroke, Macular 
degeneration 








F 50 Cystic Kidney disease 






Renal tract calcification (or 
nephrolithiasis or 
nephrocalcinosis) 
Nephrocalcinosis, CKD stage 3 
7 c.67delGd F 64 Cystic Kidney disease Multiple renal cysts, HBP 
8 c.400delA M 64 Cystic Kidney disease 
Multiple renal cysts (cortical), liver cysts, CKD stage 




M 59 Cystic Kidney disease Multiple renal cysts, HBP 
CKD Chronic Kidney Disease; HBP High blood pressure 
a CKD stage not reported in the database b This patient is also included in Table 1 (individual III.1 of the pedigree P) c 
Identification of a variant of unknown significance in PKD2 c.2140A>G (p.Lys714Glu): conservative change affecting a 
moderately conserved residue, variant reported twice in GnomAD d Identification of a variant of unknown significance in PKD1 
c.4085C>T (p.Ser1362Phe): fairly conservative change affecting a residue conserved in orthologs but not in the protein domain 
(PKD repeats), variant reported once in GnomAD. 
Figure legends 
Figure 1- Distribution of the 17 previously reported and newly described pathogenic variants 
identified in DNAJB11 (27 pedigrees), and domain organization of DNAJB11. DNAJB11 is a 358-amino-
acid protein comprising a highly conserved J domain, with a characteristic His-Pro-Asp (HPD) motif 
through which it interacts with the chaperone BiP, a substrate-binding domain, and a dimerization 
domain. While most of the variants identified are loss of function variants, the only two pathogenic 
missense variants described occurred in the J domain.  
(a) Nucleotide substitution causing a disruption of the initiation codon (b) pathogenic variants previously 
reported in Am J Hum Genet. 2018 May 3;102(5):832-844 (c) Last nucleotide of exon 6, the substitution 
is predicted to weaken the donor site (BDGP, 0.06 to <0.01; HSF 83.39 to 72.52, and the motif entropy 
score for the donor site goes from +4.51 to -4.94)
Figure 2. Kidney functions and renal survival in DNAJB11-affected individuals. (A) CKD EPI eGFR values 
are plotted against age in 77 patients from 27 families (comprising the seven previously reported and the 
twenty newly described pedigrees). Renal function does not differ according to sex. (B) Kaplan-Meier 
curves show that renal survival does not differ in male and female subjects with a median age at ESRD of 
75 years (0.95 CI, 72.5-77.5 years). 
Figure 3. Representative abdominal imaging of fifteen individuals from twelve families. Computed 
tomography (CT) are displayed for six individuals (non-contrast-enhanced in A, E, G, L; contrast-enhanced 
in D and M), and magnetic resonance imaging (MRI) for 10 individuals, T2-weighted in B, C, F, H, I, K, N, 











































Table S1. Distribution of the probands recruited in the Genomes England 100,000 Project in the “renal 
and urinary tracts disorders” category 
Disease category Number of probands 
aHUS  42 
Amyloidosis  91 
CAKUT 1083 
Cystic kidney disease 1304 
Severe Early-onset hypertension  234 
Familial hematuria 246 
Proteinuric renal disease  288 
Renal tract calcification (or Nephrolithiasis/nephrocalcinosis) 290 
Renal tubular acidosis and other electrolyte disorders 58 
Unexplained kidney failure in young people 346 
Rare multisystem ciliopathy disorders 24 
Total 3934 
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c.100C>T ; p.R34*
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renal cysts, liver cysts, renal failure, and/or genetically diagnosed and gray symbols indicate case subjects
where clinical information is unavailable. Clinical characteristics are detailed in Table 1. The DNAJB11
that DNA sequencing proved the mutation; blue DNA symbol denotes the absence of the pathogenic variant. 
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c.532delA ; p.T178fs

